サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1606343

肺がん診断薬市場、診断検査タイプ-世界の産業分析、規模、シェア、成長、動向、予測、2024年～2034年

Lung Cancer Diagnostics Market, Diagnostic Test Type - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版日
ページ情報
英文 228 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
肺がん診断薬市場、診断検査タイプ-世界の産業分析、規模、シェア、成長、動向、予測、2024年～2034年
出版日: 2024年10月14日
発行: Transparency Market Research
ページ情報: 英文 228 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

肺がん診断薬市場 - 調査範囲

TMRの調査レポート「肺がん診断薬の世界市場」は、2024年から2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018年から2034年までの世界の肺がん診断薬市場の収益と予測を提供しています。また、2024年から2034年までの世界の肺がん診断薬市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、肺がん診断薬市場を推察しました。

市場スナップショット
2023年の市場規模 151億米ドル
2034年の市場規模 348億米ドル
CAGR 7.9%

本レポートでは、世界の肺がん診断薬市場の競合情勢について掘り下げています。世界の肺がん診断薬市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTなどが、本レポートで紹介している世界の肺がん診断薬市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界の市場分析と予測、2020年～2034年

第5章 主要洞察

  • 産業界における最近の技術進歩
  • 肺がん診断ツールとしての液体生検の出現に関する考察
  • 価格動向
  • 主要地域/国における規制状況
  • ポーターのファイブフォース分析
  • PESTEL分析
  • バリューチェーン分析
  • 新規参入者のための市場開拓戦略
  • エンドユーザーにとっての重要な購入指標
  • 主要な業界イベント（パートナーシップ、コラボレーション、製品承認、合併と買収、資金調達と投資）
  • 競合が提供する製品のベンチマーク

第6章 世界の市場分析と予測：診断テストタイプ別

  • イントロダクションと定義
  • 主な調査結果/ 進展
  • 市場金額予測：診断テストタイプ別、2020年～2034年
    • 生検
      • 針生検
      • 経気管支生検
      • 胸腔鏡下生検
      • 液体生検
        • 循環腫瘍細胞（CTC）
        • 循環腫瘍DNA
        • 遊離RNA（cfRNA）
        • エクソソーム
        • プロテオーム解析
      • その他
    • 画像検査
      • 磁気共鳴画像（MRI）
      • コンピュータ断層撮影（CT）スキャン
      • 胸部超音波検査
      • 陽電子放出断層撮影（PET）
      • その他の画像検査
    • 分子検査
    • その他
  • 診断テストタイプ別の市場の魅力

第7章 世界の市場分析と予測：製品タイプ別

  • イントロダクションと定義
  • 主な調査結果/ 進展
  • 市場金額予測：製品タイプ別、2020年～2034年
    • 機器
    • 消耗品
  • 製品タイプ別の市場の魅力

第8章 世界の市場分析と予測：がんタイプ別

  • イントロダクションと定義
  • 主な調査結果/ 進展
  • 市場金額予測：がんタイプ別、2020年～2034年
    • 非小細胞肺がん（NSCLC）
    • 小細胞肺がん（SCLC）
  • がんタイプ別の市場の魅力

第9章 世界の市場分析と予測：エンドユーザー別

  • イントロダクションと定義
  • 主な調査結果/ 進展
  • 市場金額予測：エンドユーザー別、2020年～2034年
    • 病院
    • クリニック
    • 診断・画像診断センター
    • がん調査機関
  • エンドユーザー別の市場の魅力

第10章 世界の市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 地域別の市場の魅力

第11章 北米の市場分析と予測

  • 米国
  • カナダ

第12章 欧州の市場分析と予測

  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域

第13章 アジア太平洋地域の市場分析と予測

  • 中国
  • 日本
  • インド
  • オーストラリアとニュージーランド
  • その他アジア太平洋地域

第14章 ラテンアメリカの市場分析と予測

  • ブラジル
  • メキシコ
  • その他ラテンアメリカ地域

第15章 中東・アフリカの市場分析と予測

  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

第16章 競合情勢

  • 市場企業-競合マトリックス（企業階層と規模別）
  • 市場シェア分析企業別（2023年）
  • 企業プロファイル
    • Abbott
    • Siemens Healthcare
    • GE Healthcare
    • Amoy Diagnostics Co.
    • Boditech Med, Inc.
    • Danaher
    • F. Hoffmann-La Roche
    • INOVIQ
    • MedGenome
    • Quest Diagnostics Incorporated
    • DiaSorin S.p.A.
    • Oncocyte Corporation
    • QIAGEN
    • Thermo Fisher Scientific, Inc.
    • NanoString Technologies
    • Biodesix
    • Other Prominent Players
図表

List of Tables

  • Table 01: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2020-2034
  • Table 02: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Biopsy, 2020-2034
  • Table 03: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Liquid Biopsy, 2020-2034
  • Table 04: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Imaging Tests, 2020-2034
  • Table 05: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Product Type, 2020-2034
  • Table 06: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 07: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by End-users, 2020-2034
  • Table 08: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Region, 2020-2034
  • Table 09: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country, 2020-2034
  • Table 10: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2020-2034
  • Table 11: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Biopsy, 2020-2034
  • Table 12: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Liquid Biopsy, 2020-2034
  • Table 13: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Imaging Tests, 2020-2034
  • Table 14: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Product Type , 2020-2034
  • Table 15: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 16: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 17: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2020-2034
  • Table 19: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Biopsy, 2020-2034
  • Table 20: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Liquid Biopsy, 2020-2034
  • Table 21: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Imaging Tests, 2020-2034
  • Table 22: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Product Type , 2020-2034
  • Table 23: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 24: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 25: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 26: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2020-2034
  • Table 27: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Biopsy, 2020-2034
  • Table 28: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Liquid Biopsy, 2020-2034
  • Table 29: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Imaging Tests, 2020-2034
  • Table 30: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Product Type , 2020-2034
  • Table 31: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 32: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 33: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 34: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2020-2034
  • Table 35: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Biopsy, 2020-2034
  • Table 36: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Liquid Biopsy, 2020-2034
  • Table 37: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Imaging Tests, 2020-2034
  • Table 38: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Product Type , 2020-2034
  • Table 39: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 40: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 41: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 42: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2020-2034
  • Table 43: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Biopsy, 2020-2034
  • Table 44: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Liquid Biopsy, 2020-2034
  • Table 45: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Imaging Tests, 2020-2034
  • Table 46: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Product Type , 2020-2034
  • Table 47: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Cancer Type, 2020-2034
  • Table 48: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 01: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, 2017-2031
  • Figure 02: Global Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Diagnostic Test Type, 2023 and 2034
  • Figure 03: Global Lung Cancer Diagnostics Market Share Analysis, by Diagnostic Test Type, 2023
  • Figure 04: Global Lung Cancer Diagnostics Market Share Analysis, by Diagnostic Test Type, 2034
  • Figure 05: Global Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test Type, 2024-2034
  • Figure 06: Global Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Product Type, 2023 and 2034
  • Figure 07: Global Lung Cancer Diagnostics Market Share Analysis, by Product Type, 2023
  • Figure 08: Global Lung Cancer Diagnostics Market Share Analysis, by Product Type, 2034
  • Figure 09: Global Lung Cancer Diagnostics Market Attractiveness Analysis, by Type, 2024-2034
  • Figure 10: Global Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Cancer Type, 2023 and 2034
  • Figure 11: Global Lung Cancer Diagnostics Market Share Analysis, by Cancer Type, 2023
  • Figure 12: Global Lung Cancer Diagnostics Market Share Analysis, by Cancer Type, 2034
  • Figure 13: Global Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 14: Global Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
  • Figure 15: Global Lung Cancer Diagnostics Market Share Analysis, by End-user, 2023
  • Figure 16: Global Lung Cancer Diagnostics Market Share Analysis, by End-user, 2034
  • Figure 17: Global Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 18: Global Lung Cancer Diagnostics Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 19: Global Lung Cancer Diagnostics Market Share Analysis, by Region, 2023
  • Figure 20: Global Lung Cancer Diagnostics Market Share Analysis, by Region, 2034
  • Figure 21: Global Lung Cancer Diagnostics Market Attractiveness Analysis, by Region, 2023-2034
  • Figure 22: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 23: North America Lung Cancer Diagnostics Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 24: North America Lung Cancer Diagnostics Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 25: North America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Diagnostic Test Type, 2023 and 2034
  • Figure 26: North America Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test Type, 2024-2034
  • Figure 27: North America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Product Type, 2023 and 2034
  • Figure 28: North America Lung Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
  • Figure 29: North America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Cancer Type , 2023 and 2034
  • Figure 30: North America Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 31: North America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
  • Figure 32: North America Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 33: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 34: Europe Lung Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 35: Europe Lung Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 36: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Diagnostic Test Type, 2023 and 2034
  • Figure 37: Europe Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test Type, 2024-2034
  • Figure 38: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Product Type, 2023 and 2034
  • Figure 39: Europe Lung Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
  • Figure 40: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Cancer Type , 2023 and 2034
  • Figure 41: Europe Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 42: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
  • Figure 43: Europe Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 44: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 45: Asia Pacific Lung Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 46: Asia Pacific Lung Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 47: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Diagnostic Test Type, 2023 and 2034
  • Figure 48: Asia Pacific Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test Type, 2024-2034
  • Figure 49: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Product Type, 2023 and 2034
  • Figure 50: Asia Pacific Lung Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
  • Figure 51: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Cancer Type , 2023 and 2034
  • Figure 52: Asia Pacific Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 53: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
  • Figure 54: Asia Pacific Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 55: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 56: Latin America Lung Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 57: Latin America Lung Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 58: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Diagnostic Test Type, 2023 and 2034
  • Figure 59: Latin America Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test Type, 2024-2034
  • Figure 60: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Product Type, 2023 and 2034
  • Figure 61: Latin America Lung Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
  • Figure 62: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Cancer Type , 2023 and 2034
  • Figure 63: Latin America Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 64: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
  • Figure 65: Latin America Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 66: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
  • Figure 67: Middle East & Africa Lung Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 68: Middle East & Africa Lung Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 69: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Diagnostic Test Type, 2023 and 2034
  • Figure 70: Middle East & Africa Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test Type, 2024-2034
  • Figure 71: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Product Type, 2023 and 2034
  • Figure 72: Middle East & Africa Lung Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
  • Figure 73: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Cancer Type , 2023 and 2034
  • Figure 74: Middle East & Africa Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2024-2034
  • Figure 75: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
  • Figure 76: Middle East & Africa Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
目次
Product Code: TMRGL74159

Lung Cancer Diagnostics Market - Scope of Report

TMR's report on the global lung cancer diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global lung cancer diagnostics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global lung cancer diagnostics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the lung cancer diagnostics market.

Market Snapshot
Market Value in 2023US$ 15.1 Bn
Market Value in 2034US$ 34.8 Bn
CAGR7.9%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global lung cancer diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global lung cancer diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global lung cancer diagnostics market.

The report delves into the competitive landscape of the global lung cancer diagnostics market. Key players operating in the global lung cancer diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global lung cancer diagnostics market profiled in this report.

Key Questions Answered in Global lung cancer diagnostics Market Report:

  • What is the sales/revenue generated by lung cancer diagnostics across all regions during the forecast period?
  • What are the opportunities in the global lung cancer diagnostics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Lung Cancer Diagnostics Market - Research Objectives and Research Approach

The comprehensive report on the global lung cancer diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global lung cancer diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global lung cancer diagnostics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Lung Cancer Diagnostics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Lung Cancer Diagnostics Market Analysis and Forecasts, 2020-2034
    • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

  • 5.1. Recent Technological Advancements in Lung Cancer Diagnostics Industry
  • 5.2. Insights on Emergence of Liquid Biopsy as a Lung Cancer Diagnostic Tool
  • 5.3. Lung Cancer Diagnostics Pricing Trends
  • 5.4. Regulatory Landscape across Key Regions / Countries
  • 5.5. PORTER's Five Forces Analysis
  • 5.6. PESTEL Analysis
  • 5.7. Value Chain Analysis
  • 5.8. Go-To Market Strategy for New Entrants
  • 5.9. Key Purchase Metrics for End-users
  • 5.10. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions, funding and investments)
  • 5.11. Benchmarking of the Products Offered by the Competitors

6. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Diagnostic Test Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Diagnostic Test Type, 2020-2034
    • 6.3.1. Biopsy
      • 6.3.1.1. Needle biopsy
      • 6.3.1.2. Transbronchial biopsy
      • 6.3.1.3. Thoracoscopic biopsy
      • 6.3.1.4. Liquid Biopsy
        • 6.3.1.4.1. Circulating Tumor Cells (CTCs)
        • 6.3.1.4.2. Circulating Tumor DNA
        • 6.3.1.4.3. Cell-Free RNA (cfRNA)
        • 6.3.1.4.4. Exosomes
        • 6.3.1.4.5. Proteomic Analysis
      • 6.3.1.5. Others
    • 6.3.2. Imaging Tests
      • 6.3.2.1. Magnetic Resonance Imaging (MRI)
      • 6.3.2.2. Computed Tomography (CT) Scan
      • 6.3.2.3. Chest Ultrasound
      • 6.3.2.4. Positron Emission Tomography (PET)
      • 6.3.2.5. Other Imaging Tests
    • 6.3.3. Molecular Testing
    • 6.3.4. Others
  • 6.4. Market Attractiveness By Diagnostic Test Type

7. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Product Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Product Type, 2020-2034
    • 7.3.1. Instruments
    • 7.3.2. Consumables
  • 7.4. Market Attractiveness By Product Type

8. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Cancer Type

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Cancer Type, 2020-2034
    • 8.3.1. Non-small cell lung cancer (NSCLC)
    • 8.3.2. Small cell lung cancer (SCLC)
  • 8.4. Market Attractiveness By Cancer Type

9. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast By End-user, 2020-2034
    • 9.3.1. Hospitals
    • 9.3.2. Clinics
    • 9.3.3. Diagnostic & Imaging Centers
    • 9.3.4. Cancer Research Institutes
  • 9.4. Market Attractiveness By End-user

10. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast By Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness By Region

11. North America Lung Cancer Diagnostics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
    • 11.2.1. Biopsy
      • 11.2.1.1. Needle biopsy
      • 11.2.1.2. Transbronchial biopsy
      • 11.2.1.3. Thoracoscopic biopsy
      • 11.2.1.4. Liquid Biopsy
        • 11.2.1.4.1. Circulating Tumor Cells (CTCs)
        • 11.2.1.4.2. Circulating Tumor DNA
        • 11.2.1.4.3. Cell-Free RNA (cfRNA)
        • 11.2.1.4.4. Exosomes
        • 11.2.1.4.5. Proteomic Analysis
      • 11.2.1.5. Others
    • 11.2.2. Imaging Tests
      • 11.2.2.1. Magnetic Resonance Imaging (MRI)
      • 11.2.2.2. Computed Tomography (CT) Scan
      • 11.2.2.3. Chest Ultrasound
      • 11.2.2.4. Positron Emission Tomography (PET)
      • 11.2.2.5. Other Imaging Tests
    • 11.2.3. Molecular Testing
    • 11.2.4. Others
  • 11.3. Market Value Forecast By Product Type, 2020-2034
    • 11.3.1. Instruments
    • 11.3.2. Consumables
  • 11.4. Market Value Forecast By Cancer Type, 2020-2034
    • 11.4.1. Non-small cell lung cancer (NSCLC)
    • 11.4.2. Small cell lung cancer (SCLC)
  • 11.5. Market Value Forecast By End-user, 2020-2034
    • 11.5.1. Hospitals
    • 11.5.2. Clinics
    • 11.5.3. Diagnostic & Imaging Centers
    • 11.5.4. Cancer Research Institutes
  • 11.6. Market Value Forecast By Country, 2020-2034
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Diagnostic Test Type
    • 11.7.2. By Product Type
    • 11.7.3. By Cancer Type
    • 11.7.4. By End-user
    • 11.7.5. By Country

12. Europe Lung Cancer Diagnostics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
    • 12.2.1. Biopsy
      • 12.2.1.1. Needle biopsy
      • 12.2.1.2. Transbronchial biopsy
      • 12.2.1.3. Thoracoscopic biopsy
      • 12.2.1.4. Liquid Biopsy
        • 12.2.1.4.1. Circulating Tumor Cells (CTCs)
        • 12.2.1.4.2. Circulating Tumor DNA
        • 12.2.1.4.3. Cell-Free RNA (cfRNA)
        • 12.2.1.4.4. Exosomes
        • 12.2.1.4.5. Proteomic Analysis
      • 12.2.1.5. Others
    • 12.2.2. Imaging Tests
      • 12.2.2.1. Magnetic Resonance Imaging (MRI)
      • 12.2.2.2. Computed Tomography (CT) Scan
      • 12.2.2.3. Chest Ultrasound
      • 12.2.2.4. Positron Emission Tomography (PET)
      • 12.2.2.5. Other Imaging Tests
    • 12.2.3. Molecular Testing
    • 12.2.4. Others
  • 12.3. Market Value Forecast By Product Type, 2020-2034
    • 12.3.1. Instruments
    • 12.3.2. Consumables
  • 12.4. Market Value Forecast By Cancer Type, 2020-2034
    • 12.4.1. Non-small cell lung cancer (NSCLC)
    • 12.4.2. Small cell lung cancer (SCLC)
  • 12.5. Market Value Forecast By End-user, 2020-2034
    • 12.5.1. Hospitals
    • 12.5.2. Clinics
    • 12.5.3. Diagnostic & Imaging Centers
    • 12.5.4. Cancer Research Institutes
  • 12.6. Market Value Forecast By Country / Sub-region, 2020-2034
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Spain
    • 12.6.5. Italy
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Diagnostic Test Type
    • 12.7.2. By Product Type
    • 12.7.3. By Cancer Type
    • 12.7.4. By End-user
    • 12.7.5. By Country / Sub-region

13. Asia Pacific Lung Cancer Diagnostics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
    • 13.2.1. Biopsy
      • 13.2.1.1. Needle biopsy
      • 13.2.1.2. Transbronchial biopsy
      • 13.2.1.3. Thoracoscopic biopsy
      • 13.2.1.4. Liquid Biopsy
        • 13.2.1.4.1. Circulating Tumor Cells (CTCs)
        • 13.2.1.4.2. Circulating Tumor DNA
        • 13.2.1.4.3. Cell-Free RNA (cfRNA)
        • 13.2.1.4.4. Exosomes
        • 13.2.1.4.5. Proteomic Analysis
      • 13.2.1.5. Others
    • 13.2.2. Imaging Tests
      • 13.2.2.1. Magnetic Resonance Imaging (MRI)
      • 13.2.2.2. Computed Tomography (CT) Scan
      • 13.2.2.3. Chest Ultrasound
      • 13.2.2.4. Positron Emission Tomography (PET)
      • 13.2.2.5. Other Imaging Tests
    • 13.2.3. Molecular Testing
    • 13.2.4. Others
  • 13.3. Market Value Forecast By Product Type, 2020-2034
    • 13.3.1. Instruments
    • 13.3.2. Consumables
  • 13.4. Market Value Forecast By Cancer Type, 2020-2034
    • 13.4.1. Non-small cell lung cancer (NSCLC)
    • 13.4.2. Small cell lung cancer (SCLC)
  • 13.5. Market Value Forecast By End-user, 2020-2034
    • 13.5.1. Hospitals
    • 13.5.2. Clinics
    • 13.5.3. Diagnostic & Imaging Centers
    • 13.5.4. Cancer Research Institutes
  • 13.6. Market Value Forecast By Country / Sub-region, 2020-2034
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Diagnostic Test Type
    • 13.7.2. By Product Type
    • 13.7.3. By Cancer Type
    • 13.7.4. By End-user
    • 13.7.5. By Country / Sub-region

14. Latin America Lung Cancer Diagnostics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
    • 14.2.1. Biopsy
      • 14.2.1.1. Needle biopsy
      • 14.2.1.2. Transbronchial biopsy
      • 14.2.1.3. Thoracoscopic biopsy
      • 14.2.1.4. Liquid Biopsy
        • 14.2.1.4.1. Circulating Tumor Cells (CTCs)
        • 14.2.1.4.2. Circulating Tumor DNA
        • 14.2.1.4.3. Cell-Free RNA (cfRNA)
        • 14.2.1.4.4. Exosomes
        • 14.2.1.4.5. Proteomic Analysis
      • 14.2.1.5. Others
    • 14.2.2. Imaging Tests
      • 14.2.2.1. Magnetic Resonance Imaging (MRI)
      • 14.2.2.2. Computed Tomography (CT) Scan
      • 14.2.2.3. Chest Ultrasound
      • 14.2.2.4. Positron Emission Tomography (PET)
      • 14.2.2.5. Other Imaging Tests
    • 14.2.3. Molecular Testing
    • 14.2.4. Others
  • 14.3. Market Value Forecast By Product Type, 2020-2034
    • 14.3.1. Instruments
    • 14.3.2. Consumables
  • 14.4. Market Value Forecast By Cancer Type, 2020-2034
    • 14.4.1. Non-small cell lung cancer (NSCLC)
    • 14.4.2. Small cell lung cancer (SCLC)
  • 14.5. Market Value Forecast By End-user, 2020-2034
    • 14.5.1. Hospitals
    • 14.5.2. Clinics
    • 14.5.3. Diagnostic & Imaging Centers
    • 14.5.4. Cancer Research Institutes
  • 14.6. Market Value Forecast By Country / Sub-region, 2020-2034
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Diagnostic Test Type
    • 14.7.2. By Product Type
    • 14.7.3. By Cancer Type
    • 14.7.4. By End-user
    • 14.7.5. By Country / Sub-region

15. Middle East & Africa Lung Cancer Diagnostics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
    • 15.2.1. Biopsy
      • 15.2.1.1. Needle biopsy
      • 15.2.1.2. Transbronchial biopsy
      • 15.2.1.3. Thoracoscopic biopsy
      • 15.2.1.4. Liquid Biopsy
        • 15.2.1.4.1. Circulating Tumor Cells (CTCs)
        • 15.2.1.4.2. Circulating Tumor DNA
        • 15.2.1.4.3. Cell-Free RNA (cfRNA)
        • 15.2.1.4.4. Exosomes
        • 15.2.1.4.5. Proteomic Analysis
      • 15.2.1.5. Others
    • 15.2.2. Imaging Tests
      • 15.2.2.1. Magnetic Resonance Imaging (MRI)
      • 15.2.2.2. Computed Tomography (CT) Scan
      • 15.2.2.3. Chest Ultrasound
      • 15.2.2.4. Positron Emission Tomography (PET)
      • 15.2.2.5. Other Imaging Tests
    • 15.2.3. Molecular Testing
    • 15.2.4. Others
  • 15.3. Market Value Forecast By Product Type, 2020-2034
    • 15.3.1. Instruments
    • 15.3.2. Consumables
  • 15.4. Market Value Forecast By Cancer Type, 2020-2034
    • 15.4.1. Non-small cell lung cancer (NSCLC)
    • 15.4.2. Small cell lung cancer (SCLC)
  • 15.5. Market Value Forecast By End-user, 2020-2034
    • 15.5.1. Hospitals
    • 15.5.2. Clinics
    • 15.5.3. Diagnostic & Imaging Centers
    • 15.5.4. Cancer Research Institutes
  • 15.6. Market Value Forecast By Country / Sub-region, 2020-2034
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Diagnostic Test Type
    • 15.7.2. By Product Type
    • 15.7.3. By Cancer Type
    • 15.7.4. By End-user
    • 15.7.5. By Country / Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 16.2. Market Share Analysis By Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. Abbott
      • 16.3.1.1. Company Overview
      • 16.3.1.2. Financial Overview
      • 16.3.1.3. Product Portfolio
      • 16.3.1.4. Business Strategies
      • 16.3.1.5. Recent Developments
    • 16.3.2. Siemens Healthcare
      • 16.3.2.1. Company Overview
      • 16.3.2.2. Financial Overview
      • 16.3.2.3. Product Portfolio
      • 16.3.2.4. Business Strategies
      • 16.3.2.5. Recent Developments
    • 16.3.3. GE Healthcare
      • 16.3.3.1. Company Overview
      • 16.3.3.2. Financial Overview
      • 16.3.3.3. Product Portfolio
      • 16.3.3.4. Business Strategies
      • 16.3.3.5. Recent Developments
    • 16.3.4. Amoy Diagnostics Co.
      • 16.3.4.1. Company Overview
      • 16.3.4.2. Financial Overview
      • 16.3.4.3. Product Portfolio
      • 16.3.4.4. Business Strategies
      • 16.3.4.5. Recent Developments
    • 16.3.5. Boditech Med, Inc.
      • 16.3.5.1. Company Overview
      • 16.3.5.2. Financial Overview
      • 16.3.5.3. Product Portfolio
      • 16.3.5.4. Business Strategies
      • 16.3.5.5. Recent Developments
    • 16.3.6. Danaher
      • 16.3.6.1. Company Overview
      • 16.3.6.2. Financial Overview
      • 16.3.6.3. Product Portfolio
      • 16.3.6.4. Business Strategies
      • 16.3.6.5. Recent Developments
    • 16.3.7. F. Hoffmann-La Roche
      • 16.3.7.1. Company Overview
      • 16.3.7.2. Financial Overview
      • 16.3.7.3. Product Portfolio
      • 16.3.7.4. Business Strategies
      • 16.3.7.5. Recent Developments
    • 16.3.8. INOVIQ
      • 16.3.8.1. Company Overview
      • 16.3.8.2. Financial Overview
      • 16.3.8.3. Product Portfolio
      • 16.3.8.4. Business Strategies
      • 16.3.8.5. Recent Developments
    • 16.3.9. MedGenome
      • 16.3.9.1. Company Overview
      • 16.3.9.2. Financial Overview
      • 16.3.9.3. Product Portfolio
      • 16.3.9.4. Business Strategies
      • 16.3.9.5. Recent Developments
    • 16.3.10. Quest Diagnostics Incorporated
      • 16.3.10.1. Company Overview
      • 16.3.10.2. Financial Overview
      • 16.3.10.3. Product Portfolio
      • 16.3.10.4. Business Strategies
      • 16.3.10.5. Recent Developments
    • 16.3.11. DiaSorin S.p.A.
      • 16.3.11.1. Company Overview
      • 16.3.11.2. Financial Overview
      • 16.3.11.3. Product Portfolio
      • 16.3.11.4. Business Strategies
      • 16.3.11.5. Recent Developments
    • 16.3.12. Oncocyte Corporation
      • 16.3.12.1. Company Overview
      • 16.3.12.2. Financial Overview
      • 16.3.12.3. Product Portfolio
      • 16.3.12.4. Business Strategies
      • 16.3.12.5. Recent Developments
    • 16.3.13. QIAGEN
      • 16.3.13.1. Company Overview
      • 16.3.13.2. Financial Overview
      • 16.3.13.3. Product Portfolio
      • 16.3.13.4. Business Strategies
      • 16.3.13.5. Recent Developments
    • 16.3.14. Thermo Fisher Scientific, Inc.
      • 16.3.14.1. Company Overview
      • 16.3.14.2. Financial Overview
      • 16.3.14.3. Product Portfolio
      • 16.3.14.4. Business Strategies
      • 16.3.14.5. Recent Developments
    • 16.3.15. NanoString Technologies
      • 16.3.15.1. Company Overview
      • 16.3.15.2. Financial Overview
      • 16.3.15.3. Product Portfolio
      • 16.3.15.4. Business Strategies
      • 16.3.15.5. Recent Developments
    • 16.3.16. Biodesix
      • 16.3.16.1. Company Overview
      • 16.3.16.2. Financial Overview
      • 16.3.16.3. Product Portfolio
      • 16.3.16.4. Business Strategies
      • 16.3.16.5. Recent Developments
    • 16.3.17. Other Prominent Players
      • 16.3.17.1. Company Overview
      • 16.3.17.2. Financial Overview
      • 16.3.17.3. Product Portfolio
      • 16.3.17.4. Business Strategies
      • 16.3.17.5. Recent Developments